About ADARx Pharmaceuticals
ADARx Pharmaceuticals is a company based in San Diego (United States) founded in 2019 by Zhen Li. ADARx Pharmaceuticals has raised $352.5 million across 7 funding rounds from investors including BlackRock, T. Rowe Price and Marshall Wace. The company has 44 employees. ADARx Pharmaceuticals offers products and services including RNA Medicines. ADARx Pharmaceuticals operates in a competitive market with competitors including Poseida Therapeutics, Senti Biosciences, CRISPR Therapeutics, WhiteLab Genomics and OXGENE, among others.
- Total Equity Funding$352.5M (USD)
in 7 rounds
- Latest Funding Round$200M (USD), Series C
Aug 2023
- InvestorsBlackRock
& 17 more
- Employee Count44
Products & Services of ADARx Pharmaceuticals
ADARx Pharmaceuticals offers a comprehensive portfolio of products and services, including RNA Medicines.
Treatments that silence disease-causing genes via RNA technology
Funding Insights of ADARx Pharmaceuticals
ADARx Pharmaceuticals has successfully raised a total of $352.5M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $200 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $352.5M
- Total Rounds 7
- Last Round Series C — $200M
- First Round $5M
(Jan 2020)
- Investors Count 18
All 7 funding rounds of ADARx Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | $200M | Series C | – | Bain Capital Life Sciences, TCG Crossover | |
| Jan 2023 | $46M | Series C | – | Ascenta Capital | |
| Jul 2021 | $75M | Series C | – | SR One, Orbimed | |
| May 2021 | $15.5M | Series B | – | – | – |
| Nov 2020 | $6M | Series A | – | – | – |
| Jul 2020 | $5M | Series A | – | – | – |
| Jan 2020 | $5M | Series A | – | – | – |
18 investors in total: 18 institutional.
Investors in ADARx Pharmaceuticals
ADARx Pharmaceuticals has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include BlackRock, T. Rowe Price and Marshall Wace.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | – | baincapitallifesciences.com | Boston, United States | |
- | – | tcgcrossover.com | - | |
Venture capital is provided to healthcare startups by Commodore Capital. | – | commodorecapital.com | New York, United States | |
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
Long-short equity strategies are managed through specialized hedge funds. | 1997 | mwam.com | London, United Kingdom | |
Venture capital firm focused on tech sectors | – | venrock.com | Palo Alto, United States | |
Venture capital and private equity firm | – | vivocapital.com | Palo Alto, United States | |
Ascenta Capital is focused on biopharma investment and growth. | – | ascentacap.com | - | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States |
Investor details for ADARx Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ADARx Pharmaceuticals
44 people are tracked at ADARx Pharmaceuticals (14 in leadership, 9 in board & advisors, 21 in team); the tracked headcount is 44.
| Name | Role | Group |
|---|---|---|
Zhen Li | Co-Founder & CEO | Leadership |
Ajim Tamboli | Chief Financial Officer | Leadership |
Nora Dimon | Executive Director Clinical Development | Leadership |
Adam Shubin, CPA | Senior Director, Corporate Controller | Leadership |
Kin Chiu Fong | Director Of Chemistry | Leadership |
Christopher Claeboe | Senior Vice President Operations | Leadership |
A. Robert MacLeod, Ph.D | Chief Scientific Officer | Leadership |
Huey-Jing Huang | Director of Biology | Leadership |
Caroline Desponts | Director, Discovery Biology | Leadership |
Kimberly Fultz | Director of Translational Biology | Leadership |
Rui Zhu | VP, Research & Development | Leadership |
Richard Wong | Bioanalytical Director | Leadership |
Jia Hu | Associate VP Of Biometrics | Leadership |
Ting Zhang | Senior Director, Business Development and Strategy | Leadership |
Chen Yu | Director | Board & advisors |
Ricky Sun | Director | Board & advisors |
Erez Chimovits | Director | Board & advisors |
Sheila Gujrathi | Chair | Board & advisors |
Carl L. Gordon | Director | Board & advisors |
Yuan Sun | Director | Board & advisors |
24 more people are available in the full profile.
Complete people profiles for ADARx Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ADARx Pharmaceuticals
ADARx Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ADRX in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onNASDAQ: ADRX
- Listed entityADARx Pharmaceuticals, Inc.
- Exchange sectorCommercial services
- ISINUS00654F1057
- Share price$17.68 (+1.99% on the day) · 2026-10-08
- Market capitalisation$1.96B
- Volume (last session)420,188
Timeline of ADARx Pharmaceuticals
3 dated milestones of ADARx Pharmaceuticals across 4 years, from founding to its latest funding, stage changes and deals.
- Founded ADARx Pharmaceuticals is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series C, of $200.0M.
Competitors of ADARx Pharmaceuticals
ADARx Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Senti Biosciences, CRISPR Therapeutics, WhiteLab Genomics and OXGENE, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| sentibio.com | 2016 | San Francisco, United States | $158M | – | Cell-based therapies for cancer treatment are developed. | |
| crisprtx.com | 2013 | Basel, Switzerland | $127M | – | Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing. | |
| whitelabgx.com | 2019 | Paris, France | $10.25M | – | AI platform for drug discovery and development is provided. | |
| oxgene.com | 2011 | Oxford, United Kingdom | $28.09M | 102 | Provider of a platform for mammalian cell engineering | |
| genprex.com | 2009 | Austin, United States | $3.11M | 28 | Therapeutics for molecular-level cancer treatment are developed. | |
| aldevron.com | 1998 | Fargo, United States | – | 747 | Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications | |
| 64xbio.com | 2017 | San Francisco, United States | $59.65M | 18 | Cell and gene therapies for multiple diseases are developed. | |
| tome.bio | 2021 | Cambridge, United States | $213M | – | CRISPR-based gene insertion platform for genomic medicines is developed. |
Detailed competitors of ADARx Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ADARx Pharmaceuticals
The website of ADARx Pharmaceuticals (adarx.com) receives about 6.4K visits a month.
- Monthly visits6.4K
▲ 69.6% vs previous month
Websites whose visitors overlap most with ADARx Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| clinicomp.com | 100% | – | #523,501 | View details | |
| carihealth.com | 100% | – | – | View details | |
| baincapitallifesciences.com | 99% | – | #3,217,310 | View details | |
kadencehealthcare.com | kadencehealthcare.com | 99% | – | #7,313,283 | – |
| zerigohealth.com | 99% | 5.4K | #3,508,305 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for ADARx Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Adarx Pharmaceuticals
Complete news archive for ADARx Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ADARx Pharmaceuticals
10 companies that operate in the same segment as ADARx Pharmaceuticals (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ADARx Pharmaceuticals
ADARx Pharmaceuticals was founded in 2019 and raised its 1st funding round 1 year after it was founded.
ADARx Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Zhen Li is the current CEO of ADARx Pharmaceuticals. They have also founded this company.
ADARx Pharmaceuticals is a funded company, having raised a total of $352.5M across 7 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Jan 2020.
ADARx Pharmaceuticals has 44 employees.
ADARx Pharmaceuticals was founded in 2019 in San Diego, United States. Genetic therapeutic solutions are developed to target and edit single point mutations on RNA transcripts. Precise modifications are made to nucleotide sequences in transcripts, enabling production of desired proteins from genomic templates. Operations focus on biotechnology applications for therapeutic editing, with leadership provided by co-founder and CEO Zhen Li.
ADARx Pharmaceuticals's top competitors include CRISPR Therapeutics, Senti Biosciences and Poseida Therapeutics.
ADARx Pharmaceuticals offers RNA Medicines.
Yes, ADARx Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ADRX.
ADARx Pharmaceuticals has 18 investors. Key investors include BlackRock, T. Rowe Price, Marshall Wace, Orbimed, and HBM Healthcare Investments.
ADARx Pharmaceuticals operates through Adarx Pharmaceuticals Inc.